Narsoplimab is under clinical development by Omeros and currently in Phase III for IgA Nephropathy (Berger’s Disease). According to GlobalData, Phase III drugs for IgA Nephropathy (Berger’s Disease) have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Narsoplimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Narsoplimab overview

OMS-721 is under development for the treatment of thrombotic microangiopathies (TMAs) including atypical hemolytic uremic syndrome (aHUS) and thrombotic thrombocytopenic purpura (TTP), thrombotic microangiopathy, steroid-dependent Immunoglobulin A- IgA nephropathy (Berger's disease), lupus nephritis, C3 glomerulopathy and membranous nephropathy including dense deposit disease. OMS-721 can be administered by subcutaneous and intravenous routes as a solution. The drug candidate is a human monoclonal antibody which targets MASP-2. It was also under development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), wet macular degeneration, ischemia-reperfusion injury, myocardial infarction, ischemic stroke and diabetic neuropathy.

OMS-721 is also under development for the treatment of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome causing coronavirus 2 (SARS-CoV-2).

Omeros overview

Omeros is a biopharmaceutical company that discovers, develops and commercializes small-molecule and protein therapeutics for large-market and orphan indications. The company’s marketed product, Omidria is a phenylephrine and ketorolac injection for use during cataract surgery or replacement of intraocular lens (IOL). The company is investigating its product candidates for use in arthroscopic, ophthalmological, and other surgical procedures including thrombotic microangiopathies, mediated glomerulopathies, addictive and compulsive disorders among others. It is also evaluating preclinical product candidates for treatment of alternative pathway disorders, central nervous system disorders, metabolic, oncologic, musculoskeletal and other disorders. Omeros is headquartered in Seattle, Washington, the US.

For a complete picture of Narsoplimab’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.